US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6664227B1
(en)
|
1996-03-01 |
2003-12-16 |
Genetics Institute, Llc |
Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
|
EP0812913A3
(en)
*
|
1996-06-12 |
1999-08-04 |
Smithkline Beecham Corporation |
HR-1 receptor, a receptor of the cytokine receptors family
|
US6335426B1
(en)
|
1996-06-14 |
2002-01-01 |
Bayer Corporation |
T-cell selective interleukin-4 agonists
|
US5986059A
(en)
|
1996-06-14 |
1999-11-16 |
Bayer Corporation |
T-cell selective interleukin-4 agonists
|
US6028176A
(en)
|
1996-07-19 |
2000-02-22 |
Bayer Corporation |
High-affinity interleukin-4 muteins
|
US6287801B1
(en)
*
|
1996-07-22 |
2001-09-11 |
Smithkline Beecham Corporation |
Nucleic acids encoding the G-protein coupled receptor HNFDS78
|
SK287578B6
(en)
*
|
1996-12-20 |
2011-03-04 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US6852508B1
(en)
|
1997-02-28 |
2005-02-08 |
Genetics Institute, Llc |
Chemokine with amino-terminal modifications
|
US6100387A
(en)
|
1997-02-28 |
2000-08-08 |
Genetics Institute, Inc. |
Chimeric polypeptides containing chemokine domains
|
US7198789B2
(en)
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
US6057128A
(en)
|
1998-03-17 |
2000-05-02 |
Genetics Institute, Inc. |
MU-1, member of the cytokine receptor family
|
EP1093457B8
(en)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US20010021380A1
(en)
*
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP2431054A3
(en)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
AU6842701A
(en)
|
2000-06-16 |
2002-01-14 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
EP2338512A1
(en)
|
2000-11-28 |
2011-06-29 |
MedImmune, LLC |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
PT1355919E
(en)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Molecules with extended half-lives, compositions and uses thereof
|
EP1683865A3
(en)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Mammalian proteins and in particular CD200
|
DE60236643D1
(en)
*
|
2001-02-22 |
2010-07-22 |
Univ New York State Res Found |
opiate receptors
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
ATE470676T1
(en)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
ANTI-VEGF-2 ANTIBODIES
|
CN100594935C
(en)
|
2001-05-25 |
2010-03-24 |
人体基因组科学有限公司 |
Antibodies that immunospecifically bind to trail receptors
|
EP1499352A4
(en)
|
2002-04-12 |
2006-10-11 |
Medimmune Inc |
Recombinant anti-interleukin-9 antibodies
|
ATE530577T1
(en)
|
2002-05-10 |
2011-11-15 |
Purdue Research Foundation |
EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF APPLICATION THEREOF
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
JP4459810B2
(en)
|
2002-08-14 |
2010-04-28 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB specific antibody and method of use thereof
|
US20040198686A1
(en)
*
|
2003-01-18 |
2004-10-07 |
Rothenberg Marc Elliot |
Regulation of allergen induced gene
|
EP1444989A1
(en)
|
2003-02-07 |
2004-08-11 |
Giorgio Dr. Stassi |
Sensitizing cells for apoptosis by selectively blocking cytokines
|
ES2457538T3
(en)
|
2003-02-20 |
2014-04-28 |
Seattle Genetics, Inc. |
Anti-CD70-drug antibody conjugates and their use for the treatment of cannula and immune disorders
|
BRPI0408315A
(en)
|
2003-03-14 |
2006-03-07 |
Wyeth Corp |
isolated antibody, pharmaceutical composition, isolated nucleic acid, expression vector, host cell, methods of producing an antibody, generating an antibody or antigen binding fragment, regulating an immune response, treating or preventing a disorder associated with an immune cell in a patient to treat or prevent a hyperproliferative disorder in a patient, and diagnostic kit
|
US7354584B2
(en)
|
2003-04-11 |
2008-04-08 |
Medimmune, Inc. |
Recombinant IL-9 antibodies
|
DE602004011770T2
(en)
*
|
2003-06-12 |
2009-02-05 |
Eli Lilly And Co., Indianapolis |
FUSION PROTEIN
|
EA008831B1
(en)
*
|
2003-06-12 |
2007-08-31 |
Эли Лилли Энд Компани |
Glp-1 analog fusion proteins
|
ES2458636T3
(en)
|
2003-08-18 |
2014-05-06 |
Medimmune, Llc |
Humanization of antibodies
|
WO2005058961A2
(en)
|
2003-12-12 |
2005-06-30 |
Amgen Inc. |
Antibodies specific for human galanin, and uses thereof
|
WO2005066348A2
(en)
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
WO2005097184A2
(en)
|
2004-03-26 |
2005-10-20 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
EP2194064A1
(en)
*
|
2004-05-13 |
2010-06-09 |
Eli Lilly & Company |
FGF-21 fusion proteins
|
US7501121B2
(en)
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
AR049390A1
(en)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
|
AU2005286770A1
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US7635754B2
(en)
*
|
2004-09-22 |
2009-12-22 |
Aerovance, Inc. |
Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
AU2005307831A1
(en)
|
2004-11-17 |
2006-05-26 |
Amgen, Inc. |
Fully human monoclonal antibodies to IL-13
|
US20090232807A1
(en)
*
|
2004-12-22 |
2009-09-17 |
Eli Lilly And Company |
Glp-1 analog fusion protein formulations
|
JP5153613B2
(en)
|
2005-03-18 |
2013-02-27 |
メディミューン,エルエルシー |
Antibody framework shuffle
|
EP1871418B1
(en)
|
2005-04-19 |
2014-03-19 |
Seattle Genetics, Inc. |
Humanized anti-cd70 binding agents and uses thereof
|
CN102321174B
(en)
|
2005-05-06 |
2013-10-16 |
津莫吉尼蒂克斯公司 |
IL-31 monoclonal antibodies and methods of use
|
KR20080025174A
(en)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
Antibody formulations having optimized aggregation and fragmentation profiles
|
AU2006311661B2
(en)
|
2005-11-07 |
2011-05-26 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
EP2027291A2
(en)
|
2006-04-27 |
2009-02-25 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
ATE520032T1
(en)
|
2006-06-21 |
2011-08-15 |
Apogenix Gmbh |
DIFFERENTIAL CYTOKINE EXPRESSION IN HUMAN CANCER
|
WO2008019199A2
(en)
|
2006-06-26 |
2008-02-14 |
Macrogenics, Inc. |
FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
SG170032A1
(en)
|
2006-08-28 |
2011-04-29 |
Kyowa Hakko Kirin Co Ltd |
Antagonistic human light-specific human monoclonal antibodies
|
BRPI0715660B8
(en)
|
2006-09-01 |
2021-05-25 |
Zymogenetics Inc |
isolated antibody that binds to human IL-31; and, use of a monoclonal antibody
|
AU2007313300A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
US8455622B2
(en)
|
2006-12-01 |
2013-06-04 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
WO2008121615A2
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Inc. |
Antibody formulation
|
PT2164868E
(en)
|
2007-05-04 |
2015-08-04 |
Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa |
Engineered rabbit antibody variable domains and uses thereof
|
AU2008255027B2
(en)
|
2007-05-14 |
2013-10-03 |
Astrazeneca Ab |
Methods of reducing eosinophil levels
|
JP5744522B2
(en)
|
2007-12-07 |
2015-07-08 |
ザイモジェネティクス, インコーポレイテッド |
Humanized antibody molecule specific for IL-31
|
CA2711736A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
ES2458541T3
(en)
|
2008-05-02 |
2014-05-06 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
KR101030978B1
(en)
*
|
2008-07-10 |
2011-04-28 |
(주) 에이프로젠 |
Recombinant Expression Vectors for Animal Cells
|
EP2815766B1
(en)
|
2008-08-05 |
2017-07-05 |
Novartis AG |
Compositions and methods for antibodies targeting complement protein C5
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
EA201171259A1
(en)
|
2009-04-22 |
2012-05-30 |
Мерк Патент Гмбх |
ANTIBODY HYBRID PROTEINS WITH MODIFIED FCRN BINDING SITES
|
ES2548030T3
(en)
|
2009-06-01 |
2015-10-13 |
Medimmune, Llc |
Molecules with prolonged half-lives and uses thereof
|
MX2012000121A
(en)
|
2009-06-22 |
2012-03-07 |
Medimmune Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION.
|
ES2629167T3
(en)
|
2009-07-20 |
2017-08-07 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases
|
EP2464657B1
(en)
|
2009-08-10 |
2015-04-01 |
MorphoSys AG |
Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
|
DK2464664T3
(en)
|
2009-08-13 |
2016-01-18 |
Crucell Holland Bv |
ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) AND METHODS FOR USING IT
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
AU2011249783B9
(en)
|
2010-05-06 |
2014-11-06 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies
|
US9290573B2
(en)
|
2010-05-06 |
2016-03-22 |
Novartis Ag |
Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
JP5744196B2
(en)
|
2010-07-09 |
2015-07-08 |
クルセル ホランド ベー ヴェー |
Anti-human respiratory polynuclear virus (RSV) antibodies and methods of use
|
MY192639A
(en)
|
2010-07-09 |
2022-08-29 |
Bioverativ Therapeutics Inc |
Factor ix polypeptides and methods of use thereof
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
DK2606070T3
(en)
|
2010-08-20 |
2017-03-27 |
Novartis Ag |
Antibodies for the epidermal growth factor receptor 3 (HER3)
|
KR20140018837A
(en)
|
2010-08-27 |
2014-02-13 |
스템 센트알엑스 인코포레이티드 |
Notum protein modulators and methods of use
|
US9458231B2
(en)
|
2010-09-03 |
2016-10-04 |
Stemcentrx, Inc. |
Modulators and methods of use
|
DK2635607T3
(en)
|
2010-11-05 |
2019-11-18 |
Zymeworks Inc |
STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
TWI585106B
(en)
|
2010-12-08 |
2017-06-01 |
艾伯維史坦森特瑞斯有限責任公司 |
Novel modulators and methods of use
|
EP2668210B1
(en)
|
2011-01-26 |
2020-06-17 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
SA112330278B1
(en)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
Novel modulators and methods of use
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
US20150044208A1
(en)
|
2011-09-23 |
2015-02-12 |
Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa |
Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
JP2014533247A
(en)
|
2011-11-01 |
2014-12-11 |
バイオノミクス インコーポレイテッド |
Antibodies and methods of treating cancer
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
WO2013067060A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
JP2015502741A
(en)
|
2011-11-04 |
2015-01-29 |
ノバルティス アーゲー |
Low density lipoprotein related protein 6 (LRP6)-half-life extended construct
|
ES2899956T3
(en)
|
2011-11-04 |
2022-03-15 |
Zymeworks Inc |
Stable heterodimeric antibody design with mutations in the Fc domain
|
JP2015505828A
(en)
|
2011-12-02 |
2015-02-26 |
イーライ リリー アンド カンパニー |
Anti-glucagon antibodies and uses thereof
|
EA201491107A1
(en)
|
2011-12-05 |
2014-11-28 |
Новартис Аг |
ANTIBODIES TO THE RECEPTOR EPIDERMAL GROWTH FACTOR 3 (HER3), DIRECTED TO DOMAIN II HER3
|
CN108341873B
(en)
|
2011-12-05 |
2022-03-25 |
诺华股份有限公司 |
Antibodies to epidermal growth factor receptor 3(HER3)
|
BR112014015111A2
(en)
|
2011-12-21 |
2017-06-13 |
Novartis Ag |
p-factor targeting antibody compositions and processes
|
EP2794653B1
(en)
|
2011-12-23 |
2019-03-13 |
Pfizer Inc |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
EP2817338B1
(en)
|
2012-02-24 |
2017-07-26 |
AbbVie Stemcentrx LLC |
Dll3 modulators and methods of use
|
MX2014010094A
(en)
|
2012-02-24 |
2014-09-16 |
Stem Centrx Inc |
Anti sez6 antibodies and methods of use.
|
AU2013258834B2
(en)
|
2012-05-10 |
2017-09-07 |
Zymeworks Bc Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
|
NZ630363A
(en)
|
2012-07-25 |
2018-09-28 |
Celldex Therapeutics Inc |
Anti-kit antibodies and uses thereof
|
CA2887129A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
SG11201503567SA
(en)
|
2012-12-05 |
2015-06-29 |
Novartis Ag |
Compositions and methods for antibodies targeting epo
|
CA2891686A1
(en)
|
2012-12-18 |
2014-06-26 |
Novartis Ag |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
AU2014218730B2
(en)
|
2013-02-22 |
2018-12-13 |
Abbvie Stemcentrx Llc |
Novel antibody conjugates and uses thereof
|
US20160067337A1
(en)
|
2013-03-14 |
2016-03-10 |
Bristol-Myers Squibb Company |
Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
CN103265637B
(en)
*
|
2013-06-04 |
2015-10-21 |
江苏众红生物工程创药研究院有限公司 |
A kind of Recombinant Swine IL-4-Fc fusion rotein and encoding gene thereof and expression method
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
UY35620A
(en)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
|
AR096601A1
(en)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
|
CA2922478C
(en)
|
2013-08-26 |
2020-09-29 |
MabVax Therapeutics, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewisa
|
CA2922547C
(en)
|
2013-08-28 |
2020-03-10 |
Stemcentrx, Inc. |
Site-specific antibody conjugation methods and compositions
|
WO2015031541A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Novel sez6 modulators and methods of use
|
JP2016540826A
(en)
|
2013-11-04 |
2016-12-28 |
ファイザー・インク |
Anti-EFNA4 antibody-drug conjugate
|
BR112016017248A8
(en)
|
2014-01-24 |
2018-04-17 |
Ngm Biopharmaceuticals Inc |
antibody or fragment thereof, binding agent, transgenic animal, hybridoma, vector, pharmaceutical composition, fgf19 and / or fgf21-like signaling induction method, method for activating a klotho beta / fgf receptor complex, method for improving metabolism of glucose in an individual, method of detecting klotho beta, use of antibody or fragment thereof, use of pharmaceutical composition, treatment method and method for improving metabolic parameters
|
EP3107576A4
(en)
|
2014-02-21 |
2017-09-06 |
Abbvie Stemcentrx LLC |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
AU2015240599B2
(en)
|
2014-04-04 |
2020-11-19 |
Bionomics, Inc. |
Humanized antibodies that bind LGR5
|
EP3143138B1
(en)
|
2014-05-13 |
2022-03-23 |
BioAtla, Inc. |
Conditionally active biological proteins
|
CN106413750B
(en)
|
2014-05-16 |
2022-04-29 |
免疫医疗有限责任公司 |
Molecules with altered neonatal Fc receptor binding with enhanced therapeutic and diagnostic properties
|
NZ764877A
(en)
|
2014-06-04 |
2023-12-22 |
Biontech Res And Development Inc |
Human monoclonal antibodies to ganglioside gd2
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
WO2015198243A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
DK3177642T3
(en)
|
2014-08-07 |
2022-02-21 |
Novartis Ag |
ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USING IT
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
JP2017532019A
(en)
|
2014-09-03 |
2017-11-02 |
バイオアトラ、エルエルシー |
Discovery and production of conditionally active biological proteins in the same eukaryotic cell production host
|
MA41044A
(en)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
|
WO2016094837A2
(en)
|
2014-12-11 |
2016-06-16 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
UY36449A
(en)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
|
DE112016001013T5
(en)
|
2015-03-03 |
2017-12-21 |
Kymab Limited |
ANTIBODIES, USES AND METHODS
|
EA201792561A1
(en)
|
2015-06-05 |
2018-04-30 |
Новартис Аг |
ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION
|
JOP20200312A1
(en)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
Factor xi antibodies and methods of use
|
JP6940479B2
(en)
|
2015-08-03 |
2021-09-29 |
ノバルティス アーゲー |
How to treat FGF21-related disorders
|
SI3347377T1
(en)
|
2015-09-09 |
2021-06-30 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
EA038332B1
(en)
|
2015-09-09 |
2021-08-10 |
Новартис Аг |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
MX2018003689A
(en)
|
2015-09-29 |
2018-04-30 |
Celgene Corp |
Pd-1 binding proteins and methods of use thereof.
|
KR20180064534A
(en)
|
2015-11-02 |
2018-06-14 |
바이오아트라, 엘엘씨 |
The conditionally active polypeptide
|
KR20210016479A
(en)
|
2015-12-04 |
2021-02-15 |
노파르티스 아게 |
Antibody cytokine engrafted compositions and methods of use for immunoregulation
|
KR20180089510A
(en)
|
2015-12-18 |
2018-08-08 |
노파르티스 아게 |
Antibodies targeting CD32b and methods of using the same
|
EP3405492B1
(en)
|
2016-01-21 |
2020-10-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
AU2017239038A1
(en)
|
2016-03-22 |
2018-10-04 |
Bionomics Inc |
Administration of an anti-LGR5 monoclonal antibody
|
JP7138567B2
(en)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
Antibodies against growth differentiation factor 15 and their uses
|
TW201802121A
(en)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
|
AU2017283787B2
(en)
|
2016-06-15 |
2020-09-17 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
US11306143B2
(en)
|
2016-07-06 |
2022-04-19 |
Bristol-Myers Squibb Company |
Combination of TIM-4 antagonist and PD-1 antagonist and methods of use
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
JP2019531284A
(en)
|
2016-09-19 |
2019-10-31 |
セルジーン コーポレイション |
Methods of treating immune disorders using PD-1 binding proteins
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
IL267538B1
(en)
|
2016-12-23 |
2024-01-01 |
Novartis Ag |
Anti-factor xi/xia antibodies for use in preventing, treating, managing or reducing the risk of a thromboembolic disorder or stroke in a subject
|
KR20190099256A
(en)
|
2016-12-23 |
2019-08-26 |
노파르티스 아게 |
Treatment Methods With Anti-Factor XI / XIa Antibodies
|
MX2019009498A
(en)
|
2017-02-08 |
2019-10-02 |
Novartis Ag |
Fgf21 mimetic antibodies and uses thereof.
|
US20200270334A1
(en)
|
2017-05-24 |
2020-08-27 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
CN111107868A
(en)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
Antibody cytokine transplantation proteins and methods of use
|
JOP20190271A1
(en)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use for immune related disorders
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
Human antibodies to thomsen-nouvelle (tn) antigen
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
CN112004558A
(en)
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer
|
UY38247A
(en)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
|
CN112384531A
(en)
|
2018-06-01 |
2021-02-19 |
诺华股份有限公司 |
Binding molecules against BCMA and uses thereof
|
BR112021000934A2
(en)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receiver for sight
|
UY38407A
(en)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
TREM2 STABILIZING ANTIBODIES
|
US20220169706A1
(en)
|
2019-03-28 |
2022-06-02 |
Danisco Us Inc |
Engineered antibodies
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
TW202100559A
(en)
|
2019-05-21 |
2021-01-01 |
瑞士商諾華公司 |
Cd19 binding molecules and uses thereof
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
TW202124446A
(en)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
Combination therapies with entpd2 antibodies
|
TW202138388A
(en)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
Methods of treating cancer with nonfucosylated anti-cd70 antibodies
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
JP2023523794A
(en)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
engineered immunoglobulin
|
WO2021220218A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Immunoglobulin variants
|
AU2021373366A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
JP2024502832A
(en)
|
2020-12-31 |
2024-01-23 |
アラマー バイオサイエンシーズ, インコーポレイテッド |
Binding agent molecules with high affinity and/or specificity and methods for their production and use
|
CA3221281A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
WO2023131901A1
(en)
|
2022-01-07 |
2023-07-13 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
TW202400658A
(en)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
Multispecific antibodies targeting il-13 and il-18
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|